文献速递心境障碍

抗抑郁治疗对重度抑郁障碍患者5-HT4受体结合的影响及其与临床结局和言语记忆的关联

Effect of Antidepressant Treatment on 5-HT4 Receptor Binding and Associations With Clinical Outcomes and Verbal Memory in Major Depressive Disorder.
PubMed 文献 · Biol Psychiatry · 2024-08-22

研究纳入90例中重度抑郁障碍患者,在艾司西酞普兰治疗前进行脑分子影像测量5-HT4受体结合,评估其预测第4、8或12周治疗结局的能力;40例患者在治疗8周后复查扫描,分析5-HT4受体结合变化与言语记忆及抑郁症状变化的相关性。结果显示治疗8周后新纹状体5-HT4受体结合下降9%,全局5-HT4受体结合变化与言语记忆结局相关,但与整体临床抑郁症状结局无关;治疗前5-HT4受体结合不能预测第8周临床康复状态。

要点

  • 艾司西酞普兰治疗8周后新纹状体5-HT4受体结合下降9%。
  • 全局5-HT4受体结合变化与言语记忆结局相关,但与整体临床抑郁症状结局无关。
  • 治疗前5-HT4受体结合不能预测第8周临床康复状态。

核心结论

  • 在中重度抑郁障碍患者中,选择性5-羟色胺再摄取抑制剂治疗下调新纹状体5-HT4受体水平,这与该类药物增加脑细胞外5-羟色胺的觀點一致。
  • 选择性5-羟色胺再摄取抑制剂治疗后全局脑5-HT4受体水平下调越少,言语记忆改善越多,提示5-HT4受体作为抑郁障碍治疗靶点的潜在重要性。

研究设计与样本

  • 90例中重度抑郁障碍患者在艾司西酞普兰抗抑郁治疗前接受分子脑影像测量5-HT4受体结合,评估治疗前5-HT4受体结合对第4、8或12周治疗结局的预测能力。
  • 40例患者在治疗8周后复查扫描,分析脑5-HT4受体结合变化与言语记忆变化及6项汉密尔顿抑郁评定量表评估的抑郁症状变化的相关性。

主要发现

  • 5-羟色胺能干预8周后,新纹状体5-HT4受体结合下降9%。
  • 5-HT4受体结合自基线的全局变化与言语记忆结局相关,但与整体临床抑郁症状结局无关。
  • 治疗前5-HT4受体结合不能预测第8周临床康复状态,且与6项汉密尔顿抑郁评定量表评分变化无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brain serotonin 4 receptor (5-HT4R) levels are lower in untreated patients with major depressive disorder (MDD) and are linked to verbal memory. Here, we investigated the relationship between 5-HT4R levels, clinical outcomes, and cognitive function in patients with MDD who initiated selective serotonin reuptake inhibitor drug treatment. METHODS: Ninety patients with moderate to severe depression underwent molecular brain imaging to measure 5-HT4R binding prior to antidepressant treatment with escitalopram. Pretreatment 5-HT4R binding was assessed for its ability to predict treatment outcome at weeks 4, 8, or 12. In 40 patients who were rescanned 8 weeks posttreatment, change in cerebral 5-HT4R binding was correlated with change in verbal memory and with change in depressive symptoms, as evaluated by the 6-item Hamilton Depression Rating Scale. RESULTS: After 8 weeks of serotonergic intervention, neostriatal 5-HT4R binding was reduced by 9%. Global change in 5-HT4R binding from baseline was associated with verbal memory outcomes, but not with overall clinical depressive symptom outcomes. Pretreatment 5-HT4R binding did not predict clinical recovery status at week 8 and was not associated with change in the 6-item Hamilton Depression Rating Scale scores. CONCLUSIONS: In patients with moderate to severe MDD, treatment with selective serotonin reuptake inhibitors downregulated neostriatal 5-HT4R levels, which is consistent with the notion that the drugs increase cerebral extracellular serotonin. The less global brain 5-HT4R levels were downregulated after selective serotonin reuptake inhibitors, the more verbal memory improved, highlighting the potential importance of 5-HT4R as a treatment target in MDD. The findings offer insights into mechanisms that underlie antidepressant effects and point to new directions for precision medicine treatments for MDD.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Dam VH, Köhler-Forsberg K, Ozenne B, et al. Effect of Antidepressant Treatment on 5-HT4 Receptor Binding and Associations With Clinical Outcomes and Verbal Memory in Major Depressive Disorder. Biol Psychiatry. 2024. PMID: 39181386. doi:10.1016/j.biopsych.2024.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。